Exon-skipping therapy for Duchenne muscular dystrophy

The Lancet

Volumn 378, Issue 9791, 2011, Pages 546-547

  Nakamura, Akinori ^a   Takeda, Shin'Ichi ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYLRIBOOLIGONUCLEOTIDE PHOSPHOROTHIONATE; ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; NONHUMAN; NOTE; OPEN READING FRAME; PRIORITY JOURNAL; SARCOLEMMA;

EID: 80051687423     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61028-3     Document Type: Note

References (11)

1. T Yokota, E Pistilli, W Duddy et al. Potential of oligonucleotide- mediated exon skipping therapy for Duchenne muscular dystrophy Expert Opin Biol Ther 7 2007 831 842 (Pubitemid 46954430)
2. V Arechavala-Gomeza, LR Graham, LJ Popplewell et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle Hum Gene Ther 18 2007 798 810 (Pubitemid 47502846)
3. S Fletcher, K Honeyman, AM Fall et al. Dystrophin expression in the mdx mouse after localized and systemic administration of a morpholino antisense oligonucleotide J Gene Med 8 2006 207 216 (Pubitemid 43250701)
4. T Yokota, QL Lu, T Partridge et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs Ann Neurol 65 2009 667 676
5. NM Goemans, M Tulinius, JT van den Akker et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy N Engl J Med 364 2011 1513 1522
6. S Cirak, V Arechavala-Gomeza, M Guglieri et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study Lancet 2011 10.1016/S0140-6736(11)60756-3 published online July 25.
7. Y Aoki, A Nakamura, T Yokota et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse Mol Ther 5 2010 e122239
8. N Jearawiriyapaisarn, HM Moulton, N Buckley et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice Mol Ther 16 2008 207 216
9. C Beroud, S Tuffery-Giraud, M Matsuo et al. Multi-exon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63 of patients with Duchenne muscular dystrophy Hum Mutat 28 2007 196 202 (Pubitemid 46233317)
10. A Nakamura, K Yoshida, K Fukushima et al. Follow-up of three cases with a large in-frame deletion of exons 45-55 in Duchenne muscular dystrophy (DMD) gene J Clin Neurol 15 2008 757 763
11. A Nakamura, S Takeda Exon-skipping therapy for Duchenne muscular dystrophy Neuropathology 29 2009 494 501